Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00352365 · ClinicalTrials.gov registry record · Phase 2
Lenalidomide in Treating Older Patients With Acute Myeloid Leukemia
A Phase 2 study of Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities and Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 41
- Enrollment target
- 20
- Study locations
NCT00352365 is a Phase 2 study of Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities and Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 41 participants, below the 117-participant average among 29 other Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities trials with a reported enrollment target (65% lower). The trial reports 20 study locations across 7 states.
The verdict
NCT00352365, a Phase 2 study of Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities and Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 41 participants
- Enrollment target
- 20
- Study locations
Study Summary
This phase II trial is studying how well lenalidomide works in treating older patients with acute myeloid leukemia with abnormal chromosome 5q. Biological therapies, such as lenalidomide, may stimulate the immune system in different ways and stop cancer cells from growing.
Conditions Studied
Interventions
- DRUG lenalidomide
Study Locations (20)
Montana
- Montana Cancer Consortium CCOP - Billings
- Northern Rockies Radiation Oncology Center - Billings
- Saint Vincent Healthcare - Billings
- Hematology-Oncology Centers of the Northern Rockies PC - Billings
- Billings Clinic - Billings
- Deaconess Medical Center - Billings
- Bozeman Deaconess Cancer Center - Bozeman
- Bozeman Deaconess Hospital - Bozeman
- Saint James Community Hospital and Cancer Treatment Center - Butte
- Berdeaux, Donald MD (UIA Investigator) - Great Falls
California
- Shasta Regional Medical Center - Redding
- Sutter Roseville Medical Center - Roseville
- Sutter General Hospital - Sacramento
Illinois
- Cancer Care Center of Decatur - Decatur
- Decatur Memorial Hospital - Decatur
- Memorial Medical Center - Springfield
Arkansas
- University of Arkansas for Medical Sciences - Little Rock
Florida
- H. Lee Moffitt Cancer Center and Research Institute - Tampa
Kansas
- Salina Regional Health Center - Salina
Michigan
- University of Michigan - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2006-06 |
| Est. Completion | 2011-07-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00352365
The ClinicalTrials.gov registry entry for NCT00352365 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 117-participant average among 29 other Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities trials with a reported enrollment target (65% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities appearing as the primary indexed condition, and to 1 intervention - of which lenalidomide is the first listed.
NCT00352365 reports 20 study locations spanning 7 distinct geographic areas - top geographies include Montana, California, Illinois.
Frequently Asked Questions
What is clinical trial NCT00352365 about?
NCT00352365 is a clinical study titled "Lenalidomide in Treating Older Patients With Acute Myeloid Leukemia". This phase II trial is studying how well lenalidomide works in treating older patients with acute myeloid leukemia with abnormal chromosome 5q. Biological therapies, such as lenalidomide, may stimulate the immune system in different ways and stop cancer cells from growing.
What is the current status of trial NCT00352365?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 41 participants. The study started on 2006-06. Estimated completion is 2011-07-01.
What conditions does trial NCT00352365 study?
This clinical trial studies the following conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2).
What interventions are being tested in trial NCT00352365?
The interventions under investigation include: lenalidomide (DRUG).
Who is sponsoring clinical trial NCT00352365?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00352365 being conducted?
This trial has 20 study locations across Arkansas, California, Florida, Illinois, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Total Marrow and Lymphoid Irradiation and Chemotherapy Before DSCT in Treating Patients With High-Risk ALL or AML
ACTIVE NOT RECRUITING · Phase 2
-
Infusion of Off-the-Shelf Expanded Cord Blood Cells to Augment Cord Blood Transplant in Patients With Hematologic Malignancies
COMPLETED · Phase 2
-
CCI-779 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, or Chronic Myelogenous Leukemia in Blastic Phase
COMPLETED · Phase 2
-
Azacitidine in Treating Patients With Relapsed Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Who Have Undergone Stem Cell Transplant
COMPLETED · Phase 2
-
Decitabine and Total-Body Irradiation Followed By Donor Bone Marrow Transplant and Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
COMPLETED · Phase 2
-
Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer
COMPLETED · Phase 2
Explore more on PlainTrial
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
All registered trials for this condition
Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
All registered trials for this condition
Arkansas
All trials with a study site in Arkansas
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.